Monday , February 20 2017
Home / Therapies / SGLT-2 Therapy Center / Christophe Arbet-Engels, MD, Q2: Empagliflozin FDA Review Process

Christophe Arbet-Engels, MD, Q2: Empagliflozin FDA Review Process

Dr. Christophe Arbet-Engels explains how empagliflozin is being submitted to the FDA for treatment of diabetes indications and that there are different subgroups under this category. The FDA reviews the data and then may or may not grant approval or ask for more data.

Christophe Arbet-Engels, MD, PhD, MBA, is vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc.

See more SGLT-2 Resources